Zylox-Tonbridge Medical Technology Co., Ltd.

HKSE 2190.HK

Zylox-Tonbridge Medical Technology Co., Ltd. Operating Income for the year ending December 31, 2023: USD -22.05 M

Zylox-Tonbridge Medical Technology Co., Ltd. Operating Income is USD -22.05 M for the year ending December 31, 2023, a 31.53% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.
  • Zylox-Tonbridge Medical Technology Co., Ltd. Operating Income for the year ending December 31, 2022 was USD -32.20 M, a 6.18% change year over year.
  • Zylox-Tonbridge Medical Technology Co., Ltd. Operating Income for the year ending December 31, 2021 was USD -34.32 M, a -129.09% change year over year.
  • Zylox-Tonbridge Medical Technology Co., Ltd. Operating Income for the year ending December 31, 2020 was USD -14.98 M, a -51.31% change year over year.
  • Zylox-Tonbridge Medical Technology Co., Ltd. Operating Income for the year ending December 31, 2019 was USD -9.90 M.
Key data
Date Operating Income EBIT EBITDA Net Income
Market news
Loading...
SV Wall Street
HKSE: 2190.HK

Zylox-Tonbridge Medical Technology Co., Ltd.

CEO Dr. Zhong Zhao Ph.D.
IPO Date July 5, 2021
Location China
Headquarters Building 1
Employees 756
Sector Health Care
Industries
Description

Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices China and internationally. It primarily offers ThromBite Clot Retriever Device, which is intended to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke; Balloon Guiding Catheter; Cylone Aspiration Catheter; ZENFLEX Pro Peripheral Drug-eluting Stent System for complex lesions and restenotic symptomatic lesions; ZENFlex Peripheral Stent System to deliver a self-expanding stent to the iliac artery, superficial femoral arteries, and/or proximal popliteal arteries through a 6F delivery system; and drug-coated percutaneous transluminal angioplasty (PTA) Balloon Catheters that are indicated for PTA of stenosis or occlusion lesions in iliac, femoral, or popliteal arteries. The company also provides Ton-Bridge extra soft coils for the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities, such as arteriovenous malformations and arteriovenous fistulae; microcatheter for coiling; distal access catheter; glycine micro catheter for professional physician to selectively inject or input control medium and/or embolic materials, and/or appropriate devices; Intracranial PTA balloon catheter; vascular snare; and snare retrieval kit for IVC filter. Zylox-Tonbridge Medical Technology Co., Ltd. was incorporated in 2012 and is headquartered in Zhejiang, the People's Republic of China.

Similar companies

2162.HK

Keymed Biosciences Inc.

USD 3.88

NA

2170.HK

Suzhou Basecare Medical Corporation Limited

USD 0.36

NA

StockViz Staff

February 1, 2025

Any question? Send us an email